We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cyprotex | LSE:CRX | London | Ordinary Share | GB00BP25RZ14 | ORD £0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 160.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 160.50 | GBX |
Cyprotex (CRX) Share Charts1 Year Cyprotex Chart |
|
1 Month Cyprotex Chart |
Intraday Cyprotex Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 31/3/2019 | 03:50 | Cyprotex - 2008 | 1,877 |
| 20/3/2019 | 00:09 | Cyprotex ADME and Biosciences. | 176 |
| 20/3/2019 | 00:06 | Cyprotex ''Now the world's largest ADMETox specialist CRO'' | 3,005 |
| 10/2/2015 | 11:31 | CRX - good times ahead | 2,933 |
| 04/6/2014 | 09:07 | Cyprotex - a buywell dud - dont touch it | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/7/2017 07:40 by buywell3 LiDCO had a good lift on friday , has any ex CRX holder joined the party ?I have been doing some more digging , and like what I am finding out check out todays LID post by buywell |
Posted at 23/6/2017 08:21 by buywell3 It was a long and bumpy ride but CRX got there in the endI have to say trying to find a small cap company in the Pharma Biotech sector that is making profits, has no debt and has cash to aid a sales push is next to impossible, especially at a decent entry point. I don't like to follow herds, where valuations have become stretched. However Husbod , since you stayed the course here this post is for you, and I still don't like resource stocks I might add. This new product LiDCOunity v2 seems to have the potential to gain a decent market share in the USA. Edwards is the local USA based market leader , and has been for years now But clinical evidence has put Lidco ahead of that product and two other competitors That evidence was a few years ago on an older Lidco model (still being sold), but this new model with the same algorithm (IP protected) at its core , but with many new enhanced features could now prove pivotal in gaining increased USA sales together with the much increased number of USA sales staff. Over the next 3 years I expect Lidco to accelerate its USA presence with more USA selected states being targeted for sales by the addition of more sales staff. Plus ROW sales to continue to increase particularly in Asia. Lidco has a major market share within the UK NHS in its area of expertise with around 55%, this new product should help it maintain that lead. However it is in the USA where the company will make the most money now as the new CEO has identified and built his well thought out sales strategy upon. This guy Sassone , is an experienced sales specialist, he is what the company lacked ; now that there is no debt and over £4M cash to allow a long needed and targeted sales drive , primarily into the USA and secondarily into the ROW , turnover and bigger profits should in my opinion follow. The strategy report which starts on page 5 in the link below is one of the most concise and well detailed reports I have ever read in a small cap company , The recent change of chart shape over the last year supports my view, the market likes what it is seeing and hearing from Sassone. He has been incentivised via share options on a sliding scale re increased share price which includes him benefiting if Lidco should be bought out at a higher price within the sliding scale band.see page 19 I think Edwards will buy Lidco within 3 years. |
Posted at 21/11/2016 09:53 by p1nkfish To anyone sitting on a profit in CRX I suspect you will have chance to allocate the cash realised is an efficient fashion elsewhere in he not too distant future. Cash could be king again for a while.Looking at the current market I am coming round to the idea that the sale of CRX is the best outcome. They would need more cash for the move and there is a bitter wind about to blow across all the markets that would hit CRX too. A shift down in valuations would be no surprise so the timing of this exit may be fortuotous - looking on the bright side - liberating cash. Keep an eye on Evotecs valuation as that will be telling as to what might have happened to CRX. Not immediately but in the next 12-18 months. CRX, a great British company but not immune from what may be about to hit the markets. You could always but into Evotec in future. |
Posted at 18/11/2016 17:44 by tiptop22 Having given the offer some serious thoughts,I have sent in my proxy and have voted against,I think that it is in the best interests of the company its employees,their customers that CRX remains an independent British Company,The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. Evotec The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec's revenues and be accretive to Evotec's 2017 EBITDA. Cyprotex is the world's largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)). Clearly it is on the cusp of real growth both in revenue and profits. I urge all PI's to vote against the motion. It is also my firm believe that an American buyer would be a more appropriate acquirer,the real opportunities for the technology and services that have been developed over the last 14 years or so are in the UK and the US. Surely eventually one of the big US CRO's would pay more than a 9.4% premium, if you vote against the motion CRX will attract the attentions of other suitors in due course willing to pay more than 9.4% premium, |
Posted at 19/10/2016 13:15 by meganxmas bought 4650 shares about an hour ago for about 150p and just sold for small loss. thoight had researched and was getting pretty excited but not enough ! the loan notes are a killer ... my interp is that circa £8m nominal loan notes are due for redemption in 2018 BUT at 150p share price the redemption costs will be close to £20m+. As a rough rule of thumb the repayment amount will increase by circa £4m for every 30p increase in share price. Now lets assume results are great and share price doubles over next 2 years ... only £60m mkt cap right ? ... company will need to find circa £40m to redeem the £8m of loan notes .... however some are redeemable and some convertible .. whatever either sizeable cash payment and/ or large placing. be warned ... Imo / nai / dyor |
Posted at 23/7/2016 08:51 by deadly FYI:buywell2 23 Jul'16 - 01:18 - 37 of 37 0 0 edit I suggest you all read the latest annual report on the company website There is a hidden nugget within which my take means Cyprotex have a decent large contract is now underway with a large Pharma , I know which one but it would not be prudent to say which one it was . These BIG Pharmas do NOT want their business aired in public so have told Cyprotex to stay quiet ie no RNS My gut tells me a predator/s are now looking at both SBS and CRX Current exchange rate moves have made a purchase now cheaper for those outside the UK One of them might want part of SBS but not the whole Likewise with CRX One of them might want CRX with part of SBS as an add on to include molecular diagnostics and DNA sequencing to CRX services which have expanded at a very fast clip of late. What we must hope for is that a move is not made before the interims are released as they will make a buyout price in excess of 200p possible in 2017 What I also hope will happen is that the BIG Pharma will be the one to buy CRX when another foreign offer is made , I also think I know who that will be. My take is that the BIG Pharma might even want BOTH Cyprotex and Source Bioscience to become one company as such a combination would enhance their Personalized Medicine aspirations plus gain a better foothold in the UK and NHS market (via SBS) So on the whole my hopes and dreams for the 2 companies remain What price a CRX/SBS combine would be would be interesting to ponder There would be savings and cross selling benefits to be made A profit of 10M within 3 years from such a combine as work from the USA looks set to rocket due to recent EPA workload and USA chemical testing law changes meaning more Toxicology and Endocrine Disruptor testing looks undemanding A buyout price for such a business then would be in the region of 250 Million pounds Can the BODS of both companies see the logic ? Can the major shareholders make them if the don't ? We will soon find out |
Posted at 02/4/2016 08:49 by buywell2 ....... Reasons to be Cheerful ( Part 3 ) ..........Firstly the AGM has to take place because of:- Section 656 of the Companies Act 2006 requires a public limited company whose net assets have fallen to half or less than half the amount of its called up share capital to call a general meeting to consider whether any, and if so what, steps should be taken to deal with the situation. Secondly , from the above: what steps should be taken to deal with the situation ? such steps could be a sale(whole)/part sale(ie Cyprotex UK or Cyprotex US ) /merger/strategic partnership deal/re-financing arrangement(getting rid of loan notes) to name but a few All avenues need to be explored to find the 'best value for shareholders' The company is obligated to undertake such actions and is doing it by means of a 'strategic review' Producing the results that Cyprotex has produced , with a depressed valuation in terms of the turnover, profits , cash in the bank, and improved trading due in no small part to a much improved website, has made Cyprotex an attractive target for a larger predator. Financial Highlights -- Strong revenue growth up 34.9% to GBP15.61 million (2014: GBP11.57 million) -- Gross margins increased to 77.3% (2014: 75.0%) -- Operating profit of GBP1.98 million, (2014: Operating loss, excluding goodwill impairment, of GBP0.71 million) -- Underlying EBITDA^ of GBP3.40 million (2014: GBP0.61 million) -- Cash generated from operations of GBP3.48 million (2014: used in operations GBP1.32 million) -- Underlying basic earnings^^ per share of 6.94 pence (2014: loss 19.67 pence) -- Cash of GBP5.4 million as at 31 December 2015 (2014: GBP2.9 million) Even more so with a decent outlook regarding trading prospects for 2016. Cyprotex can't stop a predator from coming along with an offer , for all we know one or more may be sniffing around as I key. I would be surprised and somewhat disappointed if they were not as in normal circumstances Cyprotex should have a market valuation of an average of 2 X its turnover and 20 X its profits. Which would be circa £35M instead of £22.5M ie the share price should be over 50% higher than it is or OVER 150P (ignoring the loan notes) In other words Cyprotex is a SCREAMING BUY at the current depressed share price. What I can't argue with however, is that IF Cyprotex improves turnover in 2016 by say 15%, less than half of the increase in 2015 , 2016 Turnover goes up to £17m and profits should come in at around £3M due to the exceptional margins of 77% that Cyprotex operates at. The market value would then be an average of 2 X 17M together with 20 X £3M Which would be £47M nearly 40% higher just 1 year later It is that 20 X profit aspect of the formula that makes ALL the difference. Which means TURNOVER has to grow in order to get it WITHOUT spending too much money Hence my addition to the thread header regarding a strategic partnership with Source BioScience , where Harwood Capital is also the main Institutional holder of shares. It is my belief that if done correctly with a simple selected targeted approach to achieve maximum benefits for both companies at minimum costs on a 50/50 basis The turnover of both and hence profits of both would increase in the first year of implementation and then grow in the second and third years. Now comes the interesting bit : Both Cyprotex and SourceBioScience service the MAJORITY of the WORLDS TOP TEN PHARMAS Both Cyprotex and SourceBioScience are specialists and excellent at what they do. The expertise is such that many of the TOP 10 WORLD's PHARMAS collaborate with them because Cyprotex and SourceBioScience have the technical nous, the IP, the assays , the predictive computer models, molecular diagnostics and testing, staff, labs , and equipment that RIVAL or in some cases exceed their own. And these are multi $ BILLION comanies But would any TOP 10 WORLD PHARMA ever buy Cyprotex or SourceBioScience ? NO .... not yet ... because they are too small in terms of Turnover and Profits An absolute minimum Turnover of £50M plus ($100M would be better) and profits of £5M ($10M would be better) would be needed before any one of the TOP 10 would make a bid. Source BioScience expect to turnover £30M in 2016 (£26.5M in 2015, profits should come in at about £3M (£2M in 2015) Like I have just outlined above Cyprotex should turnover around £17M in 2016 with profits of around £3M It will take a minimum of 5 years for either company to turnover £50M BUT If both companies form a strategic partnership their combined turnover should exceed £50M and profits exceed £5M WITHIN 12 MONTHS of such an announcement. This would be based if there was a combined increase of just 7% on expected numbers due to strategic partnership benefits in the first year after its commencement. BIG Cap companies pay DOUBLE the current share price if they want something , by BIG Cap I don't just mean the TOP 10 Pharmas I include the middle tier Pharmas as well as many Life Sciences Businesses. Hence the potential UPSIDE increases as well as the number of potential predators IF TURNOVER AND PROFITS fit the investment requirements under which such bigger companies operate. Get it ? ....... ..... Nice one Ian |
Posted at 01/4/2016 19:58 by buywell2 bahiflyerWelcome to the thread Thank-you for your views and I hope to see you posting some more along with some other advfn newbes that might get attracted as things hot up. Regarding the AGM Section 656 of the Companies Act 2006 requires a public limited company whose net assets have fallen to half or less than half the amount of its called up share capital to call a general meeting to consider whether any, and if so what, steps should be taken to deal with the situation. That big spike to 130p plus forced the AGM call However re the loan note debate and it is something that has got lots of folks panties in a bunch , has for some time , and must be very uncomfortable by now. The crux of the matter as I see it , keeping it simples , is ... The value of the embedded derivatives(loan notes) is linked to the company's share price. It may increase or decrease in line with share price movements until 30 September 2018 and is ultimately dependent on the share price of the company in the 30 days preceding 30 September 2018. |
Posted at 03/11/2015 08:52 by rico1234 I don't understand the massive positive feelings here, and maybe someone can explain because I don't understand it correctly.At maturity date CRX needs to pay back £5.1m on the loans and the total number of shares will increase with 27.5%. The money was supposedly for take-overs that would make more money than the cost of the loans. So far, everybody happy. But, so far CRX has just burned this cash without doing any significant take-overs. Last year EPS was negative, this year, despite the upbeat trading statement, we're still expecting to make a loss. Come 2018, CRX share price will fall sharply, or CRX will have not enough money to pay back the loans (and everyone will be forced to take a share conversion, which leads to a dilution of 60%+). Where am I wrong? |
Posted at 03/7/2014 17:23 by buywell2 I have decided to step back and post less ..... the future of Cyprotex like you guys have said rests now with the BIG Institutions that have taken a big holding in Cyprotex and others that will join as turnover increases and EPA contracts start to kick in. The ones like us that have been in for years will now hopefully be taken onwards and upwards by them. Comments re a USA listing made today by a few of you are valid. I have posted before that as Cyprotex USA grows by acquisitions , and I hope soon to read of another, a NASDAQ listing to access USA Investors who place a HIGHER value on Pharma Biotechs than their UK counterparts do ..... makes sound business sense. The NOMAD Singer N+1 has recently advised Xenetic BioSciences was (XEN on AIM ) now XBIO on the OTC USA exchange to go down this route. They de-listed from AIM and did a deal with a small USA existing OTC listed company to get listed and then changed the company name. By share consolodations their price has been hovering around the $1 mark and they hope to get listed on NASDAQ by Xmas this year. So it can be done, and I think the NOMAD has had some input in this regard as they did with Xenetic (same NOMAD) .... also as I have said before , same NOMAD as Source BioScience (SBS) where incidently Oryx Growth Fund recently bought a 3.2% stake. My gut feeling is within 24 months Cyprotex could be in a position to list on NASDAQ IF they still wanted to do so. I do not think they would go for a DUAL listing , Xenetic didn't , and the NOMAD advice will I believe remain the same. There are some strings however to think on......but if turnover is kept on the rise these should not be a problem. However they are: The number one reason for companies that have received de-listing notices from the Nasdaq Markets is: Failure to comply with the Nasdaq's minimum bid price requirement. So, what is this requirement? How does it come into effect? What can the company do about it? What is the requirement? The minimum bid price requirement stems from Section 5550(a)(2) of the Nasdaq's Equity Rules guide. It clearly states: "(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share." How does it come into effect? If a company closes below a $1/share bid price for 30 consecutive days, the Nasdaq sends the company a written notice. The notice states that the company is no longer in compliance with its continued listing requirements and has 180 days to regain compliance. Otherwise, the company will face delisting. What can the company do about non-compliance? As stated above, the company has 180 calendar days to regain compliance. In that time frame, if the company closes at or above a $1/share bid price for ten consecutive days, the Nasdaq will inform the company that it has regained compliance, and close the issue. So, the matter then becomes raising the share price (every stock's ultimate goal). There are a few ways a company can do this: 1.Good performance: Good financial performance is perhaps the most pure way to raise a stock's price. After all, better financials increase the company's value and thus its shares' value. This, however, is difficult and can take time; too much time in some cases. Good performance is also the hardest way to increase share price. 2.Good press: The saying goes, "any press is good press." Why? Press drives interest. When a company makes news, people notice. Issuing press releases on what the company is doing can send investors a company's way. Increased buyers result in increased volume, which can drive share price up. 3.Reverse split: We have discussed this topic time and time again. While this would most certainly raise a company's share price, it is a zero-sum transaction. That means the company's value is the same. For example, a company with 10 million shares at $0.50/share has a $5 million market cap. To regain compliance, the company enacts a 2 for 1 reverse split. The result is 5 million shares worth $1.00 each. The company is still worth just $5 million. 4.Buybacks: We have discussed this quite a bit too. When a company buys back shares, it decreases the number outstanding, increasing the value of those left. Ideally, this raises a company's price per share. However, the company must have the capital to purchase shares. If raising share price was simple, every stock would be an easy pick. However, it's not that simple. A company has to work to up its value. It has to work much harder to regain compliance if its share price has fallen below $1/share. Investors should watch companies not meeting this requirement extra close. Why are they not meeting the requirement? Often times, poor share performance is a direct reflection of poor company performance. So, find out what is going on to drive the company's stock below the $1 mark. To the investor, the underlying issue is more important than the minimum bid requirement. Although, if a company is delisted, it's visibility could drop significantlya story for another day. Bonne Chance Mes Amis |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
